Promising combo for breast cancer hits snag: trial ends early
NCT ID NCT01980277
First seen Apr 22, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This study tested a new drug (LY2780301) combined with standard chemotherapy (paclitaxel) in people with advanced breast cancer that had spread or couldn't be removed. The goal was to find the best dose and see if the combination could shrink tumors. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Geroges François Leclerd
Dijon, 21079, France
-
Institut Paoli-Calmettes
Marseille, 13008, France
Conditions
Explore the condition pages connected to this study.